

Enhancing Interdisciplinary Training through Biodesign: Development of a Tumor Margin Tracking System

Alexandra McLennan, MBE^{1,2,3}; Amanda Hudson, MBE²; Jade Lee, MBE²; Ishika Mukherjee, MBE²;
John Tran, BS¹, Savannah Morreale, MBE¹; Justin Bird, MD^{1,4}

¹Surgery Innovation Program, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX; ²Department of Bioengineering, Rice University, Houston, TX;
³School of Medicine, Baylor College of Medicine, Houston, TX; ⁴Department of Orthopedic Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX

SOFT TISSUE SARCOMA RESECTION

- **Soft tissue sarcomas** (STS) are malignancies that arise in muscles, fat, nerves, and other soft tissues.
- Affects **13,590 patients annually** in the U.S.¹
- STS recurrence rate after surgery is **40-50%**.^{2,3}



CURRENT MARGIN LABELING IS INEFFICIENT

- **Surgeons** label specimens intraoperatively with **sutures, clips, or dyes** to mark orientation post-resection.

These methods are often:

- ✗ **Imprecise**
 - ✗ **Inefficient**
 - ✗ **Inconsistent**
- Misguided Pathology Interpretation → High Risk of Recurrence

Need Statement: A way to **accurately mark** tumor margins and **track orientation** in adult patients with soft tissue sarcoma undergoing tumor resection for surgeons to **improve standardization** and **enhance communication**.

DESIGN CRITERIA

Physically labels 6 primary margins and high-risk zones (HRZ)

Effectively orients specimen


Facilitates long-term surveillance (≥ 5 years)

Correlates specimen and defect in a 1:1 manner


Enhances communications between surgeons and pathologists

DUAL-SIDED TAG APPLIER (DSTA) DESIGN

The DSTA attaches to traditional resection tools to place twin tags on adjacent margins at the point of resection.



THE BIODESIGN PROCESS



- **Stakeholder Interviews** – 15 providers interviewed
- **Observed Current Workflow** – 3 surgeries x 4 observers
- **Established Web of Mentors** – 30+ providers, engineers, consultants, and others
- **Needs Screening Performed** – Graduate students researched 4 Pillars

- **Concept Generation** – 100+ ideas using Crawford Slip, Modified Reflection, and SCAMPER methods
- **Concept Selection** – utilized screening/scoring Pugh matrices and feasibility checks
- **Selected Concept** – DSTA – advanced to iterative prototyping, CAD modeling, V&V

- **IP Strategy** – Prior art searches performed; Provisional patent filed
- **Regulatory** – FDA Class II De Novo based on risk profile and comparable technologies
- **Payment** – Disposable purchased for \$1.5K; purchased by hospitals and surgical centers; included in bundled payments for tumor resection surgery
- **Reimbursement** – CMS criteria met given cost savings and superior clinical outcomes
- **Future Steps** – Continue validation studies; Identify development and commercialization partners

IMPACT & CONCLUSION

Clinical Impact

- Tags margins at the point of resection to enhance precision and accuracy.
- Enables providers to easily relocate the prior tumor bed for targeted treatment and recurrence monitoring, facilitating timely re-intervention when necessary.

Engineering Innovation

- Validated, unique dual-tagging mechanism marks both the resected specimen and tumor bed simultaneously.
- Designed for standardization and compatibility with common surgical workflows and imaging modalities.

Educational Value

- Provided end-to-end exposure to the innovation process, from need to prototype.
- Encouraged collaboration with clinicians and engineers.

